Capitolis Liquid Global Markets LLC Has $188.91 Million Stock Position in Kenvue Inc. $KVUE

Capitolis Liquid Global Markets LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 1,116.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,950,999 shares of the company’s stock after buying an additional 10,050,999 shares during the period. Kenvue makes up 1.1% of Capitolis Liquid Global Markets LLC’s investment portfolio, making the stock its 17th biggest position. Capitolis Liquid Global Markets LLC’s holdings in Kenvue were worth $188,905,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in KVUE. Physician Wealth Advisors Inc. boosted its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at approximately $26,000. SBI Securities Co. Ltd. boosted its position in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares in the last quarter. Leonteq Securities AG acquired a new position in Kenvue in the 4th quarter valued at approximately $45,000. Finally, DV Equities LLC acquired a new position in Kenvue in the 4th quarter valued at approximately $46,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KVUE. UBS Group decreased their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Argus upgraded shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Finally, Canaccord Genuity Group upped their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.59% of the stock is currently owned by company insiders.

Kenvue Trading Down 2.2%

KVUE opened at $18.03 on Thursday. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average of $17.49 and a 200-day moving average of $17.56. The stock has a market cap of $34.61 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.40 and a beta of 0.54.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same period in the prior year, the company posted $0.24 earnings per share. Kenvue’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio is 97.65%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.